Skip to main content

Advertisement

Log in

Current state of treatment for primary cutaneous melanoma

  • REVIEW
  • Published:
Clinical and Experimental Medicine Aims and scope Submit manuscript

Abstract.

The incidence of malignant melanoma has been rising steadily for the last 30 years. Through physician and patient education, surveillance of high-risk individuals, and biopsy of any suspicious lesions, more lesions are being diagnosed earlier, where there is a high cure rate. Unfortunately many patients will still present with thicker lesions or nodal involvement, which carries a significantly worse prognosis. Over the past decade, there have been several changes in the management of primary cutaneous melanoma. These have stemmed from novel surgical approaches, a new understanding of melanoma biology, and randomized clinical trials designed to improve outcome and decrease the morbidity of therapy. This article will review the clinical evidence behind the current treatment recommendations for primary cutaneous melanoma as well as some of the emerging data on innovative immunologic-approaches to melanoma treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M. S. Sabel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chung, E.S., Sabel, M.S. & Sondak, V.K. Current state of treatment for primary cutaneous melanoma. Clin Exp Med 4, 65–77 (2004). https://doi.org/10.1007/s10238-004-0040-5

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10238-004-0040-5

Key words

Navigation